天天中文日韩熟妇天堂,国产色精品视频91色,亚洲伊人久久在线,亚洲熟女五十路,亚洲人妻丝袜在线,亚洲综合日韩在线,亚洲欧美另类熟女精品,大量国产欧美日韩久久,日韩欧美亚洲

CN

CN EN

Latest News

Latest News Media Downloads Video Center

Kexing Biopharm's clinical trial application approved for small-molecule oral drug SHEN26 Capsule against COVID-19
2022-07-17

2022-07-17

On the evening of July 17, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that it had received the Notice of Approval for Drug Clinical Trial issued by the National Medical Products Administration, indicating that the clinical trial of small-molecule oral drug SHEN26 Capsule against COVID-19 jointly developed by Shenzhen Kexing and Shenzhen Antiv was approved.
Kexing Biopharm's clinical trial application accepted for Human Interferon α2b Effervescent Capsule
2022-06-27

2022-06-27

On the evening of June 20, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that it had received the Notice of Acceptance, an administrative license document issued by the National Medical Products Administration, indicating that its clinical trial application for "Human Interferon α2b Vaginal Effervescent Capsule" was accepted.
Ma Zhiyong, Secretary of CPC Zhangqiu District Committee of Jinan City, and his delegation visit Kexing Biopharm for research
2022-05-07

2022-05-07

On May 6, 2022, Ma Zhiyong, Secretary of the CPC Zhangqiu District Committee of Jinan City, Shandong Province, and his delegation visited Kexing Biopharm to research the Company's projects and enterprise operation. Cui Ning, Vice President of Kexing Biopharm and General Manager of Shandong Business Unit, was in charge of the reception.
Kexing Biopharm Signs Exclusive Promotion Service Agreement for Infliximab (Reminton?)
2022-03-31

2022-03-31

On March 31, 2022, Kexing Biopharmaceutical Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that the Exclusive Promotion Service Agreement for Infliximab (Reminton?) in Chinese Mainland was signed with Taizhou Mabtech, granting Kexing Biopharm the exclusive promotion right of infliximab (Reminton?) in Chinese mainland.
Kexing Biopharm Establishes Holding Company for Developing Veterinary Vaccines
2022-03-15

2022-03-15

Scientific Vaccine Innovations for Harmonious Coexistence Between Humans and Animals

1 2 3 4 5

Support Hotline

0755-26546500
Online Consultation
QR Code

Scan Code Consultation

台东县| 嘉峪关市| 汕头市| 格尔木市| 陇川县| 湖南省| 蒲城县| 寿阳县| 确山县| 攀枝花市| 扬中市| 镇原县| 玉山县| 紫阳县| 金阳县| 天全县| 宁乡县| 桐城市| 左权县| 株洲县| 鄂托克前旗| 青海省| 玉山县| 灵山县| 宣城市| 宁南县| 隆安县| 旬邑县| 渝北区| 凤城市| 乌什县| 工布江达县| 许昌市| 宿迁市| 运城市| 蛟河市| 高陵县| 温州市| 台东县| 三亚市| 开化县|